| Literature DB >> 32532757 |
Afsana Afroz1, Thomas R Hird2,3, Ella Zomer2, Alice Owen2, Lei Chen3, Zanfina Ademi2, Danny Liew2, Dianna J Magliano2,3, Baki Billah2.
Abstract
AIMS: To estimate the impact of type 2 diabetes in terms of mortality, years of life lost (YLL) and productivity-adjusted life years (PALY) lost in Bangladesh.Entities:
Keywords: diabetes; epidemiology; health economics; other study design; public health
Mesh:
Year: 2020 PMID: 32532757 PMCID: PMC7295429 DOI: 10.1136/bmjgh-2020-002420
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
The age and gender-specific population and number of people living with diabetes in Bangladesh in 2017
| Age group | Men | Women | ||||
| Population* | Prevalence of diabetes (%)* | Men with diabetes (n) | Population* | Prevalence of diabetes (%)* | Women with diabetes (n) | |
| 20–24 | 7 862 660 | 1.8 | 142 542 | 7 621 330 | 3.1 | 235 700 |
| 25–29 | 7 312 030 | 2.7 | 197 467 | 7 357 770 | 4.2 | 308 150 |
| 30–34 | 6 796 110 | 3.9 | 267 674 | 7 028 330 | 5.6 | 391 801 |
| 35–39 | 6 118 590 | 5.5 | 339 234 | 6 367 610 | 7.2 | 458 686 |
| 40–44 | 5 211 850 | 7.4 | 387 166 | 5 294 190 | 8.9 | 472 611 |
| 45–49 | 4 626 430 | 9.4 | 433 997 | 4 591 970 | 10.5 | 482 417 |
| 50–54 | 4 012 750 | 11.1 | 445 988 | 3 923 260 | 11.7 | 458 192 |
| 55–59 | 2 962 960 | 12.3 | 365 906 | 2 818 620 | 12.3 | 345 557 |
| Total | 44 903 380 | 5.7 | 2 579 975 | 45 003 080 | 7.0 | 3 153 114 |
*Age and gender-specific population estimates and age and gender-specific prevalence of diabetes based on estimates by age and gender from the International Diabetes Federation Diabetes Atlas for 2017.4
Excess deaths and years of life lived in those with diabetes, and in the same cohort assuming no diabetes, over the working lifetime of the Bangladeshi population simulated from life table modelling
| Age group | Deaths in cohort with diabetes | Deaths in ‘diabetes cohort’ assuming no diabetes | Excess deaths in diabetes cohort | Years of life lived in cohort with diabetes | Years of life lived in ‘diabetes cohort’ assuming no diabetes | Years of life lost (%) |
| Men | ||||||
| 20–24 | 37 880 | 14 534 | 23 346 | 3 091 579 | 3 279 527 | 187 948 (5.7) |
| 25–29 | 52 044 | 20 627 | 31 417 | 3 949 032 | 4 194 217 | 245 185 (5.8) |
| 30–34 | 69 329 | 28 342 | 40 987 | 4 835 772 | 5 142 610 | 306 838 (6.0) |
| 35–39 | 84 858 | 35 770 | 49 088 | 5 386 737 | 5 730 419 | 343 682 (6.0) |
| 40–44 | 90 752 | 39 439 | 51 313 | 5 193 160 | 5 514 858 | 321 698 (5.8) |
| 45–49 | 90 204 | 40 391 | 49 813 | 4 610 903 | 4 870 686 | 259 784 (5.3) |
| 50–54 | 76 201 | 35 218 | 40 982 | 3 306 543 | 3 458 901 | 152 358 (4.4) |
| 55–59 | 33 603 | 15 868 | 17 735 | 1 339 258 | 1 372 462 | 33 204 (2.4) |
| Total | 534 871 | 230 189 | 304 682 | 31 712 983 | 33 563 680 | 1 850 697 (5.5) |
| Women | ||||||
| 20–24 | 66 692 | 16 794 | 49 898 | 4 711 657 | 5 035 712 | 324 054 (6.4) |
| 25–29 | 85 822 | 22 439 | 63 383 | 5 575 281 | 5 956 434 | 381 153 (6.4) |
| 30–34 | 106 562 | 28 845 | 77 717 | 6 227 373 | 6 653 708 | 426 335 (6.4) |
| 35–39 | 119 779 | 33 518 | 86 261 | 6 133 371 | 6 549 170 | 415 799 (6.3) |
| 40—44 | 114 967 | 33 217 | 81 750 | 4 950 391 | 5 275 494 | 325 103 (6.2) |
| 45–49 | 103 412 | 30 790 | 72 622 | 3 432 044 | 3 649 764 | 217 720 (6.0) |
| 50–54 | 77 001 | 22 168 | 54 833 | 3 395 268 | 3 397 913 | 2645 (0.1) |
| 55–59 | 31 236 | 8575 | 22 662 | 1 696 908 | 1 738 891 | 41 982 (2.4) |
| Total | 705 470 | 196 345 | 509 125 | 36 122 293 | 38 257 085 | 2 134 792 (5.6) |
Calculation of years of life lived was modelled in life tables with a half-cycle correction and was subject to an annual discount rate of 3%.
Productivity-adjusted life years (PALY) lived in those with diabetes, and in the same cohort assuming no diabetes, over the working lifetime of the Bangladeshi population simulated from life table modelling
| Age group | PALYs lived in cohort with diabetes | PALYs lived in ‘diabetes cohort’ assuming no diabetes | PALYs lost (%) | PALYs lost per person with diabetes |
| Men | ||||
| 20–24 | 2 562 248 | 2 972 870 | 410 621 (13.8) | 2.9 |
| 25–29 | 3 360 764 | 3 906 137 | 545 374 (14.0) | 2.8 |
| 30–34 | 4 153 176 | 4 842 933 | 689 757 (14.2) | 2.6 |
| 35–39 | 4 595 244 | 5 379 395 | 784 151 (14.6) | 2.3 |
| 40–44 | 4 334 462 | 5 092 370 | 757 908 (14.9) | 2.0 |
| 45–49 | 3 710 326 | 4 367 645 | 657 319 (15.0) | 1.5 |
| 50–54 | 2 528 227 | 2 974 315 | 446 088 (15.0) | 1.0 |
| 55–59 | 958 753 | 1 117 325 | 158 572 (14.2) | 0.4 |
| Total | 26 203 200 | 30 652 989 | 4 449 790 (14.5) | 1.7 |
| Women | ||||
| 20–24 | 1 385 921 | 1 941 747 | 555 826 (28.6) | 2.4 |
| 25–29 | 1 691 966 | 2 397 905 | 705 939 (29.4) | 2.3 |
| 30–34 | 1 887 915 | 2 721 664 | 833 749 (30.6) | 2.1 |
| 35–39 | 1 800 839 | 2 655 761 | 854 922 (32.2) | 1.9 |
| 40–44 | 1 360 367 | 2 068 313 | 707 946 (34.2) | 1.5 |
| 45–49 | 840 444 | 1 339 904 | 499 460 (37.3) | 1.0 |
| 50–54 | 672 063 | 1 108 213 | 436 149 (39.4) | 1.0 |
| 55–59 | 389 432 | 618 867 | 229 435 (37.1) | 0.7 |
| Total | 10 280 947 | 14 852 374 | 4 823 427 (32.5) | 1.5 |
Calculation of PALYs was modelled in life tables and subject to an annual discount rate of 3%.
Figure 1Economic burden of productivity loss in those with diabetes due to diabetes-related absenteeism, premature mortality and labour force dropout over the working lifespan in the Bangladeshi population.
Sensitivity and scenario analyses to assess the impact of the uncertainties around productivity, mortality and economic data inputs on productivity-adjusted life years (PALY) lost in those with diabetes in the Bangladeshi population and the associated economic impact
| PALYs lost due to diabetes | % change in PALYs lost compared with base case | GDP lost (US$ billion) | GDP lost per person with diabetes (US$) | |
| Base case | 9 273 217 | 97.4 | 16 987 | |
| Productivity indices upper uncertainty bound* | 8 773 791 | −5.4 | 92.3 | 16 098 |
| Productivity indices lower uncertainty bound* | 9 417 270 | +1.6 | 98.8 | 17 241 |
| Labour force dropout upper uncertainty bound† | 7 728 881 | −16.7 | 81.8 | 14 275 |
| Labour force dropout lower uncertainty bound† | 10 817 553 | +16.7 | 112.9 | 19 699 |
| Upper uncertainty bound of all-cause mortality risk associated with diabetes‡ | 11 159 921 | +20.5 | 118.0 | 20 574 |
| Lower uncertainty bound of all-cause mortality risk associated with diabetes‡ | 8 466 438 | −8.7 | 88.6 | 15 446 |
| Temporal trend in population mortality risk is doubled to a 2% reduction per year§ | 9 158 579 | −1.2 | 96.1 | 16 759 |
| No temporal trend in population mortality risk§ | 9 401 616 | +1.2 | 98.9 | 17 243 |
| Annual GDP growth rate is doubled to 3.6% per year¶ | 112.9 | 19.692 | ||
| No temporal trend in GDP¶ | 81.9 | 14 283 | ||
| Annual discount rate increased to 5%** | 7 691 123 | −17.1 | 79.0 | 13 780 |
| Annual discount rate reduced to 1.5%** | 10 875 985 | +17.3 | 116.5 | 20 313 |
*Sensitivity analyses 1 and 2 apply (1) a 25% reduction and (2) a 25% increase in absenteeism estimate, holding all other model inputs constant.
†Sensitivity analyses 3 and 4 apply (3) a 25% reduction and (4) a 25% increase in diabetes-related labour force dropout estimates, holding all other model inputs constant.
‡Sensitivity analyses 5 and 6 apply (5) the lower bound of the 95% CI and (6) the upper bound of the 95% CI around the estimate of relative risk of all-cause mortality associated with diabetes, holding all other model inputs constant.
§Scenario analyses 7 and 8 apply (7) double the annual reduction in mortality risk to 2% per year and (8) no temporal trend in population mortality risk, holding all other model inputs constant.
¶Sensitivity analyses 9 and 10 apply (9) double the annual growth rate in GDP to 3.6% per year and (10) no temporal trend in GDP across the model, holding all other model inputs constant. These sensitivity analyses do not affect the number of PALYs lived but do affect their assumed value and therefore the resulting GDP lost.
**Sensitivity analyses 11 and 12 apply an annual discount rate (11) increased to 5% (in line with the WHO standard annual rate) and (12) reduced to 1.5%.
GDP, gross domestic product.